Docs not fans of Valeant-Allergan mix

Share this article:

The Allergan-Valeant fight is already changing how doctors think about their prescription habits.

The Wall Street Journal reports that 44% of dermatologists and plastic surgeons polled in a Sanford Bernstein survey said they would consider Botox alternatives if Allergan becomes a Valeant subsidiary.

Bernstein analyst Ronnie Gal created the survey and notes that the answers are all well and good, but doctors have few alternatives.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.